The signaling and regulatory mechanism of the orphan receptor VLGR1 remains elusive. Results: The cleaved VLGR1 ␤-subunit constitutively coupled to G␣ i and was regulated by the VLGR1 ␣-subunit, a diseaseassociated mutation, and PDZD7. Conclusion: The VLGR1 ␤-subunit signals independently and is regulated at multiple levels. Significance: The identified new signaling mechanism may aid in the design of a VLGR1-targeted therapy.
The very large G protein-coupled receptor 1 (VLGR1) is a core component in inner ear hair cell development. Mutations in the vlgr1 gene cause Usher syndrome, the symptoms of which include congenital hearing loss and progressive retinitis pigmentosa. However, the mechanism of VLGR1-regulated intracellular signaling and its role in Usher syndrome remain elusive. Here, we show that VLGR1 is processed into two fragments after autocleavage at the G protein-coupled receptor proteolytic site. The cleaved VLGR1 ␤-subunit constitutively inhibited adenylate cyclase (AC) activity through G␣ i coupling. Co-expression of the G␣ iq chimera with the VLGR1 ␤-subunit changed its activity to the phospholipase C/nuclear factor of activated T cells signaling pathway, which demonstrates the G␣ i protein coupling specificity of this subunit. An R6002A mutation in intracellular loop 2 of VLGR1 abolished G␣ i coupling, but the pathogenic VLGR1 Y6236fsx1 mutant showed increased AC inhibition. Furthermore, overexpression of another Usher syndrome protein, PDZD7, decreased the AC inhibition of the VLGR1 ␤-subunit but showed no effect on the VLGR1 Y6236fsx1 mutant. Taken together, we identified an independent G␣ i signaling pathway of the VLGR1 ␤-subunit and its regulatory mechanisms that may have a role in the development of Usher syndrome.
Very large G protein-coupled receptor 1 (VLGR1), 4 also called Neurepin, Mass1, or GPR98, is the largest seven-transmembrane receptor and has important functions in hearing and vision systems (1, 2) . Mutations of the vlgr1 gene lead to the development of Usher syndrome, which causes congenital hearing loss and progressive retinitis pigmentosa (3) . In addition to sensory dysfunction, the mutation of vlgr1 is associated with febrile and afebrile seizures (4) .
The specific localizations of VLGR1 in the hearing and vision systems agree well with its functional significance. VLGR1 is found in the stereocilia of cochlear hair cells, forming the socalled ankle links (5, 6) . In vlgr1 knock-out mice, the ankle links are missing, the stereocilia are disorganized, and the mice are profoundly deaf (5, 6) . In the retina, VLGR1 is expressed at the periciliary membrane complex of photoreceptor cells that is involved in photoreceptor protein trafficking through the connecting cilium (7, 8) . Although there is a consensus that VLGR1 plays important roles in the hearing and vision systems, the details of VLGR1-regulated cell signaling and its function as a GPCR remain elusive.
As a seven-transmembrane receptor, VLGR1 belongs to the adhesion GPCR subfamily (or the LNB7TM subfamily) (9) . VLGR1 has a very long extracellular region, which includes a pentraxin domain and an epilepsy-associated repeat domain surrounded by 35 calx-␤ motifs. The C terminus of VLGR1 has seven transmembrane helices and an intracellular C-terminal tail, which contains a PDZ domain-binding interface important for interacting with several Usher proteins, such as Whirlin, Harmonin, and PDZD7 (10 -12) . The N-terminal extracellular region of VLGR1 and its seven transmembrane regions are connected by a "GPCR autoproteolysis-inducing (GAIN) domain," which harbors a GPCR proteolytic site (GPS). In many adhesion GPCRs, the GPS undergoes autoproteolysis that separates the receptor into two subunits. Recently, several studies have demonstrated that the cleaved ␤-subunits (containing the seventransmembrane region and the C-terminal tail) of these GPCRs independently signals by coupling to specific G protein subtypes (9, 13) .
Until now, VLGR1 was regarded as an orphan receptor. However, adenylate cyclase 6 (AC6), a downstream effector of the G␣ s and G␣ i proteins, has been shown to localize at the base of hair cell stereocilia, and this localization is altered in vlgr1 knock-out mice, suggesting a potential functional coupling between VLGR1 and intracellular cyclase activities (6) . Therefore we set out to delineate the specific G protein signaling downstream of VLGR1.
Concurrent with our study, a parallel work showed that a selective combination of various extracellular domains, transmembrane regions, and the C-terminal tail of VLGR1 resulted in extracellular calcium sensation and the activation of G␣ s and G␣ q subtypes as well as increased intracellular cAMP levels and PKC phosphorylation (14) . Here, we report that VLGR1 mediates GPCR signaling through another mechanism. VLGR1 undergoes autocleavage at the GPS, which separates the receptor into ␣-and ␤-subunits. The cleaved VLGR1 ␤-subunit activates G␣ i and blocks forskolin-induced cAMP elevation. Specific mutations in VLGR1 intracellular loops, pertussis toxin (PTX) interference, receptor-G protein fusions, and G␣ iq chimera experiments further confirmed the specific coupling of G␣ i to the VLGR1 ␤-subunit. The overexpression of another Usher protein, PDZD7, but not Whirlin or Harmonin, inhibited the VLGR1-G␣ i signaling pathway. In contrast, the Usher syndrome-associated mutant VLGR1 Y6236fsX1 showed enhanced constitutive G␣ i activity, and this activity was not inhibited by PDZD7 most likely due to its lack of a PDZ binding site. Our results indicated that an independent G␣ i signaling pathway is mediated by VLGR1 ␤-subunit and may further our understanding of the mechanisms underlying Usher syndrome.
EXPERIMENTAL PROCEDURES
Materials-The monoclonal anti-FLAG antibody (F3165), hydroxylamine (NH 2 OH) (438227), isoproterenol (I2760), and angiotensin (A2580) were purchased from Sigma. The polyclonal VLGR1 C terminus antibody (sc-21252), polyclonal antiMyc antibody (sc-789), monoclonal anti-GFP (B2, sc-9996), and monoclonal anti-actin (sc-8432) antibodies were from Santa Cruz Biotechnology. The phospho-CREB-Ser 133 (9198s) antibody was from Cell Signaling Technology. The GloSensor TM cAMP Assay (E1290) and Dual-Luciferase Reporter Assay System (E1960) were from Promega. Pertussis toxin (Bordetella pertussis, BML-G100-0050) was from Enzo Life Sciences. Cell culture medium (3097) was from BD Biosciences. Forskolin (S1612) was from Beyotime. The cAMP ELISA kit (KGE002) was from R&D Systems. The IP 3 ELISA kit was from EIAab (E2037 Ge). All other chemical and reagents were obtained from Sigma unless otherwise specified.
Constructs-Wild type vlgr1 C-terminal truncation (V gain ) (aa 5618 -6298), ␤-subunit (V ␤ ) (aa 5884 -6298), and cleaved V gain N terminus (V n ) (aa 5618 -5883) were cloned from mouse inner ear cDNA libraries using the following primers: forward, GATGATGACAAAGCCCTCGAGATGGACATCCTTGAT-GACAACCTTC and reverse, GTAGAAAAACTGCTGAAT-TCTCAGAGGTGGGTGTCAGC for V gain or GATGATGAC-AAAGCCCTCGAGTCTGTGTATGCTGTCTAC for V ␤ ; and forward, CCGCTCGAGGAGCAGAAACTCATCTCTGAA-GAGGATCTGGCTGTCTGGGGGCTTGAAG and reverse, CCGCTCGAGGAGCAGAAACTCATCTCTGAAGAGGAT-CTGTCTAGAGCTGTCTGGGGGCTTGAAG for V n . The sequences were inserted into the mammalian pcDNA3.1 or pEGFP expression vector. The receptor-effector fusion protein V gain -G␣ i2 or V gain -G␣ s was constructed with an overlapping PCR method using V gain and G protein cDNAs with the following primers: V gain -G␣ i2 -reverse, CTCACGGTGCAGC-CCATGAGGTGGGTGTCAGC; G␣ i2 -forward, GCTGACAC-CCACCTCATGGGCTGCACCGTGAG; G␣ i2 -reverse, GTAGAA-AAACTGCTGAATTCTCAGAAGAGGCCACAGTC; V gain -G␣ sreverse, CCCGAGGCAGCCCATGAGGTGGGTGTCAGC; G␣ s -forward, GCTGACACCCACCTCATGGGCTGCCTC-GGG; and G␣ s -reverse, GTAGAAAAACTGCTGAATTCTT-AGAGCAGCTCGTAC. The site-directed VLGR1 and G␣ i mutants, including the G␣ i1q , G␣ i2q , G␣ i3q , V gain -H5882A, V gain -S5884A V gain -F5988A, V gain -Y5990A, and V gain -R6002A mutants, were generated by the QuikChange mutagenesis kit (Stratagene). Plasmids with V gain -Y6236fsx1 (forward, GATG-ATGACAAAGCCCTCGAGATGGACATCCTTGATGACA-ACCTTC and reverse, CCGTCGACTGCAGAATTCCTAACC-TCCAGAAGAAGG) and V ␤ -Y6236fsx1 (forward, GATGATG-ACAAAGCCCTCGAGTCTGTGTATGCTGTCTAC and reverse, CCGTCGACTGCAGAATTCCTAACCTCCAGAAGA-AGG) were subcloned by overlapping PCR. The pcDNA3.0-A1TaR, pcDNA3-FLAG-␤ 2 -adrenergic receptor, and dopamine D2 receptor were generous gifts from Professor Robert J. Lefkowitz at Duke University. All constructs were subjected to DNA sequencing to verify sequence identities.
Animals and Cochlea Isolation-All animal care and experiments were reviewed and approved by the Animal Use Committee of the Shandong University School of Medicine. Gpr98 tm1Pwh /J mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in pathogen-free conditions at Shandong University. For cochlear protein preparation, P21 C57BL/6 and Gpr98 tm1Pwh /J mice were euthanized by rapid decapitation, the cochlea were quickly removed, and the proteins were prepared with lysis buffer as described previously (15) .
Cell Culture, Transfection, and Western Blotting-Human embryonic kidney 293 (HEK293) cells, U251 cells, and GloSensor HEK293 cells were maintained in Dulbecco's modified Eagle's medium or modified Eagle's medium, respectively, supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Thermo Scientific, Scoresby, Victoria, Australia). PC12 cells were maintained in Dulbecco's modified Eagle's medium with 5% heat-inactivated fetal bovine serum and 5% donor equine serum (Hyclone Thermo Scientific, SH30074.03). For receptor or other protein expression, plasmids carrying VLGR1 ␤-Subunit Signals through G␣ i the desired genes were transfected into cells using Lipofectamine TM 2000 (Invitrogen). To monitor protein expression levels, cells were collected 48 -72 h post-transfection with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM NaF, 1% Nonidet P-40, 2 mM EDTA, 10% glycerol, 0.25% sodium deoxycholate, 1 mM Na 3 VO 4 , 0.3 M aprotinin, 130 M Bestatin, 1 M leupeptin, 1 M Pepstatin, and 0.5% iodoamino acids). Cell lysates were subjected to end-to-end rotation for 20 min and spun at 12,000 rpm for 20 min at 4°C. Then an equal volume of 2ϫ loading buffer was added. Proteins were denatured in loading buffer and subjected to Western blot analysis. The protein bands from Western blots were quantified with ImageJ software (National Institutes of Health, Bethesda, MD).
Retina Preparation and in Vivo Transfection-Before transfection, the plasmids were prepared as follows. The vgr1 (aa 5618 -6298)-GFP or pcDNA3.1 control plasmid was mixed with 0.1 volume of 3 M sodium acetate and 2.5 volumes anhydrous ethanol. The mixture was bathed in ice for 15 min, centrifuged at 14,000 ϫ g at 4°C, and then washed and precipitated with anhydrous ethanol. The plasmids were further dried, resuspended in PBS, and adjusted to a concentration of 5 g/l.
For transfection, newborn (P0 -P3) mouse pups (C57BL/6) were anesthetized on ice for 5 min. The eyes were carefully opened by cutting along the closed eyelid using a sharp 26-gauge needle, and then a small incision was made in the sclera. A 20-m micropipette (P-1000, Sutter Instruments) was inserted into the incision until the tip of micropipette touched the opposing sclera. Then 0.5 l of high concentration plasmid DNA were slowly injected into the subretina (Nanoject II) followed by electroporation five pulses of 80 volts for 50 ms with 950-ms intervals using a Digidata 1440A pulse generator from Axon CNS Instruments (16) . Three days after electroporation, the eyes were dissected, and the retinas were isolated for further experiments.
In Vitro Cleavage of V gain Proteins-HEK293 cells were transfected with a FLAG-V gain or V gain -GFP plasmid in 10-cm plates. Forty-eight hours after transfection, cells were washed three times with ice-cold PBS and incubated with lysis buffer for 45 min with end-to-end rotation. After a 12,000 rpm centrifugation for 30 min, the supernatants were collected. One hundred micrograms of protein were added to 100 l of cleavage buffer (50 mM Tris, pH 7.5, 20 mM NaCl, and 1 mM EDTA) and incubated at 37°C for the desired time. Loading buffer was added to samples, and samples were analyzed by Western blotting. For NH 2 OH-facilitated receptor hydrolysis, the receptor was immunoprecipitated with anti-FLAG M2 affinity gel as described previously (17) . The immunoprecipitated receptors were incubated with 250 mM NH 2 OH for the indicated times before examination by Western blotting.
CREB Phosphorylation-HEK293 cells transfected with the desired plasmids were maintained in medium and starved for 8 h. After a 10-min application of 10 M forskolin or mock solution, the cells were quickly transferred to ice and incubated with cell lysis buffer. The cell lysates were subjected to Western blotting, and CREB phosphorylation levels were detected using a phospho-CREB-Ser 133 antibody. IP 3 ELISA-Cells were washed with cold PBS followed by three freeze-thaw cycles in liquid nitrogen. The cells were then lysed for another 20 min at 4°C with end-to-end rotation. After centrifugation at 12,000 rpm for 15 min at 4°C, the supernatant was collected to determine IP 3 concentrations according to the manufacturer's instructions (EIAab, E2037 Ge).
GloSensor cAMP Assay-GloSensor 22-F cells were transfected with the desired plasmids (0.8 g of total DNA) with Lipofectamine 2000 in 24-well dishes. Twenty-four hours later, cells were plated on 96-well plates at a cell density of 20,000 cells/well. Cells were maintained in culture medium for another 22 h and washed with PBS. Cells were then incubated with 100 l of equilibration medium (2% (v/v) GloSensor cAMP Reagent, 10% FBS, and 88% CO 2 -independent medium) in each well for 2 h. The basal cAMP signal was measured using a luminescence counter (Mithras LB 940). After the cAMP levels reached a steady baseline for more than 5 min, 10 M forskolin was added to determine the effects of forskolin-stimulated cAMP increase. For PTX treatment, 100 ng/ml PTX was preincubated with cells for at least 16 h. Data are presented as the mean Ϯ S.D. Statistical comparisons were performed with analysis of variance tests using GraphPad Prism5.
cAMP ELISA-HEK293 cells transfected with desired plasmids were cultured in 96-well plates. 48 h later, cells were washed three times with PBS and stimulated. After a certain time, cells were resuspended in 120 l of lysis buffer (1ϫ) with 500 M isobutylmethylxanthine for each well and then frozen at Ϫ20°C. Cells underwent two freeze-thaw cycles and then were subjected to centrifugation (600 ϫ g) for 10 min at 4°C to remove cellular debris. The supernatant were assessed for cAMP content according to the manufacturer's protocol (cAMP ELISA kit (KGE002) for R&D Systems).
NFAT Dual-Luciferase Reporter Assay-HEK293 cells were transfected using Lipofectamine 2000 in 24-well dishes with 0.8 g of total DNA, including V gain or V ␤ , G␣ i1q , G␣ i2q , G␣ i3q , A1TaR, dopamine D2 receptor, pGL3-NFAT luciferase or pGL3-Basic luciferase, and the pRL-TK plasmid (Promega, Madison, WI). Cells were cultured for 48 h and then harvested immediately following addition of 1ϫ passive lysis buffer. After incubation for 15 min at room temperature on a table shaker, cell lysates were centrifuged at 12,000 rpm for 10 min at 4°C. NFAT activity was quantified by a standard luciferase reporter gene assay and was normalized to Renilla luciferase activity (Promega). More than three independent experiments in 8 wells were performed for each Dual-Luciferase reporter assay.
Immunofluorescence-FLAG-tagged V ␤ -or V ␤ -Y6236fsx1-transfected cells grown on glass coverslips in 24-well tissue culture plates were fixed with 4% paraformaldehyde in phosphatebuffered saline. The cells were blocked and permeabilized with blocking buffer containing 0.1% Triton X-100 and 1% normal goat serum for 60 min at room temperature. Cells were then incubated sequentially with a primary anti-FLAG antibody at 4°C overnight and an appropriate secondary antibody for 1 h at room temperature. Immunofluorescence was analyzed on a Bio-Rad Radiance 2000 laser-scanning confocal microscope.
Co-immunoprecipitation-Co-immunoprecipitation experiments were performed as described previously (17) . Plasmids encoding FLAG-V gain , FLAG-V ␤ , Myc-V n , or Myc-PDZD7 and control pcDNA3.1 were transfected or co-transfected into HEK293 cells that were cultured in 150-mm dishes. After VLGR1 ␤-Subunit Signals through G␣ i AUGUST 29, 2014 • VOLUME 289 • NUMBER 35 allowing 30 h of protein expression, the cells were washed with phosphate-buffered saline containing 10 mM HEPES, pH 7.5. Cells were lysed in lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 2 mM sodium pyrophosphate, 5 mM NaF, 25 mM ␤-glycerophosphate, 1 mM EDTA, and 1 mM Na 3 VO 4 supplemented with protease inhibitor mixture (Roche Applied Science)). Cell lysates were then incubated with anti-FLAG M2 affinity gel (Sigma-Aldrich) for 4 -6 h, and the FLAG-tagged V gain or V ␤ was precipitated by centrifugation. After extensive bead washing with PBS buffer, the immunoprecipitated complexes were subjected to electrophoresis, and complex formation was detected by Western blotting with an anti-Myc antibody.
Data Analysis-All data are presented as the mean Ϯ S.D. from at least three independent experiments. Statistical comparisons were performed with analysis of variance tests using GraphPad Prism5. Significant differences were designated as follows: * and #, p Ͻ 0.05; ** and ##, p Ͻ 0.01; and *** and ###, p Ͻ 0.005. The sequence alignments were performed using T-Coffee.
RESULTS AND DISCUSSION
VLGR1 Can Be Processed into Two Fragments after Autoproteolysis-VLGR1 contains a GPS immediately preceding its seven-transmembrane domain (1) . Many adhesion GPCRs have been shown to undergo self-proteolysis at the GPS and VLGR1 ␤-Subunit Signals through G␣ i generate two subunits to form a heterodimeric complex (9, 13) . Recent crystallographic studies have discovered that the 40-residue GPS motif is located in an intact ϳ320-residue domain called the GAIN domain. Biochemical studies show that the GAIN domain of several adhesion GPCRs is both necessary and sufficient for autocleavage (18) .
The full-length VLGR1 encompasses ϳ6300 amino acids and thus is difficult to analyze by electrophoresis (1, 14) . To test whether VLGR1 can be processed into two fragments in a manner similar to other adhesion GPCRs, we made a construct of the C-terminal portion of VLGR1 (aa 5618 -6298; V gain ) that contained the intact GAIN domain, the seven-transmembrane region, and the intracellular C-terminal tail (Fig. 1A) . In cells transfected with the FLAG-V gain -expressing plasmid, a 75-kDa band was detected that is consistent with the size of full-length FLAG-V gain . Several bands with molecular masses higher than 130 kDa were also evident, presumably due to glycosylation or dimerization (Fig. 1B) . FLAG-V gain was mainly expressed as an intact protein; however, at ϳ35 kDa, a weak band corresponding to the N-terminal portion of FLAG-V gain after cleavage at GPS was also detected (Fig. 1B) . We then incubated the cell lysates at 37°C to promote FLAG-V gain autoproteolysis. The 35-kDa band corresponding to the cleaved N-terminal fragment increased abundantly, whereas the 80-kDa full-length FLAG-V gain band decreased in intensity (Fig. 1C) . Accordingly, the 45-kDa band corresponding to the cleaved C-terminal fragment of VLGR1 was detected by a specific VLGR1 C terminus antibody after incubation at 37°C (Fig. 1D) . Moreover, similar to the chemical cleavage that occurs at the GPS of other adhesion GPCRs, the autocleavage of VLGR1 can also be accelerated by the strong nucleophile NH 2 OH (Fig. 1E) (19) .
To further demonstrate the presence of the autocleavage site, we examined the effects of specific VLGR1 GPS mutations on VLGR1 autoproteolysis. Previous studies have revealed the essential role of the conserved H(L/M)(S/T) motif for autocleavage at the GPS (18, 19) . Although His 516 of EMR2 is the proton acceptor for the generation of the tetrahedral intermediate and deprotonates the hydroxyl group of Ser 518 , the deprotonated oxygen of Ser 518 is important for the nucleophilic attack of the C-N ester bond that produces two polypeptide fragments (19) . Therefore, we mutated the corresponding conserved His 5882 and Ser 5884 residues to Ala and examined their effects on VLGR1 autoproteolysis (Fig. 1F) . The V gain -H5882A mutant reduced autoproteolysis, and the V gain -S5884A mutant almost abolished autoproteolysis. These results suggested that specific autoproteolysis occurred at the GPS.
Endogenous VLGR1 has been detected in many tissues, including brain, lung, kidney, eye, and cochlea (1, 3, 5, 20 -22) . In humans, mutations in VLGR1 cause type IIC Usher syndrome, which results in congenital hearing loss and progressive retinitis pigmentosa (1, 23) . These genetic studies implied that the VLGR1 has important functions in the inner ear and retina. Therefore, we chose both the retina and cochlea as physiological models to investigate VLGR1 autocleavage along with the HEK293 cell system (Fig. 1, G and H) . We transfected pcDNA3.1 control plasmids or V gain (aa 5618 -6298)-GFP plasmids into the retina of the newborn (P0 -P3) mouse pups (C57BL/6). After 3 days of protein expression postelectroporation, mouse pup eyes were dissected, and the expression of V gain was detected with a GFP antibody. Similar to the FLAG-V gaintransfected HEK293 cells, a single band corresponding to the intact V gain -GFP size (100 kDa) was mainly detected in the V gain -transfected HEK293 cells (Fig. 1, B and G) . However, a cleaved band corresponding to the V ␤ -GFP (68 kDa) was detected in V gain -transfected retina, suggesting that autocleavage was more likely to happen in a more physiological context (Fig. 1G) . Next, we used inner ear tissue from Gpr98 tm1Pwh /J mice or their C57BL/6 wild type littermates to examine endogenous VLGR1 expression. The Gpr98 tm1Pwh /J mouse has a deletion of its seven-transmembrane and cytoplasmic regions. As shown in Fig. 1H in wild type cochlea, a 220-kDa band corresponding to VLGR1a (the shortest VLGR1 isoform) and a 45-kDa band corresponding to the VLGR1 ␤-subunit were detected by a specific VLGR1 C terminus antibody, whereas these bands were not detected in Gpr98 tm1Pwh /J mice. FIGURE 1. V gain underwent autoproteolysis that generated V ␤ . A, a schematic diagram of the structure of the VLGR1 constructs used in the study. V gain , aa 5618 -6298 of VLGR1, includes the GAIN domain, the seven-transmembrane region, and the intracellular C-terminal tail. V ␤ , aa 5884 -6298 of VLGR1, corresponds to the region from the GPS cleavage site to the C terminus and includes the seven-transmembrane region and the intracellular C-terminal tail. V n , aa 5618 -5883 of VLGR1, is the N-terminal region of the GAIN domain. The residues of the GPS are displayed, and the autoproteolytic position is indicated by an arrow. The disease-related VLGR1 mutations, Y6236fsx1 in the C terminus and R6002A in the second intracellular loop, both of which were used in this study, are highlighted. B, Western blot of V gain truncation (aa 5618 -6298). Cells were transiently transfected with N-terminal FLAG-tagged V gain and control pcDNA3.1 plasmids. The expression of V gain was detected by anti-FLAG antibody. The top arrow indicates the expression of FLAG-V gain with a calculated molecular mass of 74 kDa. The lower arrow indicates a 35-kDa band that corresponded to the molecular mass of the cleaved N-terminal V gain fragment. Several bands with molecular masses greater than 130 kDa were also detected. C and D, VLGR1 undergoes autoproteolysis in HEK293 cells. HEK293 cells were transiently transfected with plasmids to express N-terminal FLAG-tagged V gain or control pcDNA3.1 plasmid. The cell lysates were incubated at 37°C for 0 or 12 h. The cleaved and uncleaved fragments were examined using an anti-FLAG antibody (C) or a specific VLGR1 C terminus antibody (D). E, NH 2 OH-facilitated cleavage of V gain at GPS. Cells were transfected with V gain plasmids. After 48 h, cells were collected, and the cell lysates were incubated at 37°C with or without 250 mM NH 2 OH in cleavage buffer. After 16 h, most of the 74-kDa V gain bands were cleaved, generating the 30-kDa band corresponding to the N-terminal fragment of the V gain truncation. F, effects of GPS mutations on NH 2 OH-facilitated V gain cleavage. HEK293 cells were transiently transfected with plasmids containing the FLAG-tagged wild type V gain , V gain -H5882A (HA) mutant, V gain -S5884A (SA) mutant, or control pcDNA3.1. FLAG-tagged V gain was immunoprecipitated and incubated with 250 mM NH 2 OH to facilitate cleavage. The cleaved receptor was detected with an anti-FLAG antibody. G, VLGR1 underwent autoproteolysis and produced the truncated V ␤ in mouse retina. Mouse retina was transiently transfected with the control pcDNA3.1 plasmid or a plasmid encoding a C-terminal GFP-tagged V gain . Three days were allowed for protein expression, and VLGR1 expression was detected with a GFP antibody. The transient expressions of V ␤ -GFP (aa 5884 -6298) and V gain -GFP (aa 5618 -6298) in HEK293 cells were used as controls. Multiple bands were detected in GFP-tagged V gain -infected mouse retina, including the 80-kDa GFP-tagged fragment, which corresponded to the cleaved V ␤ -GFP. H, detection of endogenous VLGR1 in mouse cochlea. VLGR1 expression in the inner ear at P21 of the VLGR1 mutant mice (lacking the seven-transmembrane domain and cytoplasmic tail) (m/m) and the wild type (WT) mice were detected with a specific VLGR1 C terminus antibody. The transiently expressed FLAG-V ␤ in HEK293 cells was used as a control. A band around the same size as FLAG-V ␤ was detected with the VLGR1 C terminus antibody in WT mice but not in VLGR1 mutant mice. I, direct interaction between V ␤ and V n (aa 5618 -5883). FLAG-tagged V ␤ was co-transfected with Myc-tagged V n or control pcDNA4 plasmid. The V ␤ and its associated proteins were immunoprecipitated with an anti-FLAG antibody, and the formation of the V ␤ ⅐V n complex was detected with anti-Myc antibody. Con, control; IB, immunoblot.
Several studies have also suggested that the two cleaved subunits of the adhesion GPCRs still maintain a complex via noncovalent interactions (13, 18) . Therefore, we overexpressed the FLAG-tagged V ␤ and the Myc-tagged V n (aa 5618 -5883) in HEK293 cells. As shown in Fig. 1I , the complex formation of the two fragments of V gain was detected by co-immunoprecipitation assays.
V gain and V ␤ Constitutively Inhibit the AC Pathway-Most of the two cleaved subunits (␣-subunit corresponds to the N-terminal segment, and ␤-subunit corresponds to the C-terminal segment) of adhesion GPCRs still bind to each other to form heterodimers. In several cases, the ␤-subunit signals independently of the ␣-subunit, whereas the ␣-subunit serves as an inhibitor for the constitutive activity of the ␤-subunit (9, 13, 24). Without a known ligand, overexpression of an adhesion GPCR or its ␤-subunit constitutively activates specific signaling pathways that are normally stimulated by agonist activation (13, 24, 25) . The constitutive activities of orphan receptors have been used to characterize their downstream signaling activities (26, 27) .
Therefore, we made V ␤ (aa 5884 -6298) and examined the ability of the receptor to constitutively activate the classic G protein signaling pathways. The overexpression of V gain or V ␤ did not increase the basal intracellular cAMP levels or IP 3 accumulation, indicating that G␣ s and G␣ q , respectively, are not constitutively activated by V gain and V ␤ (Fig. 2, A and B) . In contrast, the overexpression of V gain or V ␤ significantly blocked the forskolin-induced intracellular cAMP increase, suggesting a negative regulatory role for V gain and V ␤ (Fig. 2C) . To confirm these results, we used isoproterenol to stimulate endogenous ␤ 2 -adrenergic receptor in HEK293 cells and kinetically monitored the effects of V gain or V ␤ on the isoproterenol-stimulated AC activity using the GloSensor assay. Again, the expression of V gain or V ␤ significantly suppressed the isoproterenol-induced increase in intracellular cAMP (Fig. 2D) . Compared with V gain , V ␤ displayed an enhanced constitutive activity in the inhibition of the intracellular cAMP level in both experiments.
The constitutive activity of a GPCR is often in proportion to its expression level (26) . To test whether this is also the case for VLGR1, we overexpressed various amounts of V gain or V ␤ in HEK293 GloSensor cells. In agreement with our hypothesis, increased expression of either V gain or V ␤ showed more inhibitory activity toward forskolin-induced cAMP elevation (Fig. 2,  E and F) . Consistently, the overexpression of V ␤ down-regulated the forskolin-induced phosphorylation of CREB at amino acid 133, the downstream target of AC activation, in a dose-dependent manner (Fig. 2, G and H) . To examine the V ␤ -mediated signaling in a more physiological context, we overexpressed the V ␤ in neuronal glioblastoma (astrocytoma) cell line U251 and the neuronal PC12 cell line and checked their effects on the forskolin-induced cAMP increase (Fig. 2, I-L) . Similar to the results in the HEK293 cells, the constitutive AC inhibitory activity of V ␤ is in proportion to its expression level in both U251 (Fig. 2, I and J) and PC12 cells (Fig. 2, K and L) . Taken together, these results show that V gain and the VLGR1 ␤-subunit constitutively inhibit the AC pathway and that V ␤ has a stronger effect than V gain .
G Protein Coupling Specificity of V gain and the VLGR1 ␤-Subunit-We then examined whether the constitutive activity of V gain and the VLGR1 ␤-subunit toward the regulation of intracellular cAMP levels is mediated via G␣ i using its inhibitory protein, PTX. Incubation of the cells with PTX abolished the inhibition of V gain and V ␤ on AC activity, suggesting that V gain and V ␤ are indeed coupled to G␣ i (Fig. 3A) . To further dissect the G protein coupling specificity of V gain and V ␤ , we next examined the effects of V gain -G␣ s (V gs ) and V gain -G␣ i (V gi ) fusion proteins (Fig. 3, B and C) . It has been shown that putting the receptor and effector together by receptor-effector fusion GloSensor cAMP HEK293 cells were transfected with either empty vector (Con), V gain , or V ␤ and then treated with 100 ng/ml PTX for 6 h followed by stimulation with forskolin. The intracellular cAMP levels were monitored using FLIPR TETRA . ***, p Ͻ 0.005 compared with control; ###, p Ͻ 0.005 compared with non-PTX treated cells. Error bars represent S.D. B, a schematic representation of the V gi and V gs fusion proteins. The start codon of G␣ i2 or G␣ s was placed immediately after the 3Ј-end of the coding region for VLGR1. C, the expression of N-terminal FLAG-tagged V gs , V gi , and V gain were examined using a FLAG-specific antibody. D, covalently linking V gain to G␣ i leads to an enhanced constitutive activity, whereas linking V gain to G␣ s blocks its constitutive activity. GloSensor cAMP HEK293 cells were transfected with either empty vector, V gain , V gi , or V gs . The forskolin-induced cAMP increase was monitored with FLIPR TETRA . Error bars represent S.D. E, effects of overexpression of V gain , V gi , or V gs on the forskolin-induced CREB phosphorylation. CREB phosphorylation was examined using a phospho-CREB-Ser 133 -specific antibody. F, statistics of E. *, p Ͻ 0.05; **, p Ͻ 0.01; ***p Ͻ 0.005 for V gain -, V gi -, or V gs -transfected cells compared with control vector-transfected cells; #, p Ͻ 0.05 for V gi -or V gs -transfected cells compared with V gain -transfected cells. Error bars represent S.D. G, the methodology for the generation of the G␣ iq chimeric proteins. The last five C-terminal residues of the corresponding G␣ i proteins were replaced with the last five C-terminal residues of the G␣ q protein that are important for the stimulation of PLC activity. H, the plasmids encoding the G␣ q or the G␣ iq chimeric proteins were co-transfected with the control vector, V gain , or V ␤ . The activation of the G␣ iq -PLC pathway was assayed by detecting the luciferase activity of the NFAT-driven luciferase reporter gene. The known G␣ i -coupled receptor D2 receptor was used as a positive control. Error bars represent S.D. RLU, relative luciferase units; Con, control; IB, immunoblot; pCREB, phospho-CREB; D 2 R, dopamine D2 receptor.
VLGR1 ␤-Subunit Signals through G␣ i AUGUST 29, 2014 • VOLUME 289 • NUMBER 35 increases their binding affinity to agonist and increases the basal activity of the effector in the case of some GPCRs, such as GPR120 (28 -30) . Our results showed that, compared with V gain , V gi has a stronger AC inhibitory activity, whereas the V gs has a weaker activity likely due to the blockade of the interaction of V gain with endogenous G␣ i protein (Fig. 3D) . Forskolininduced CREB phosphorylation also decreased more when V gi was overexpressed than when V gain was overexpressed (Fig. 3, E  and F) .
We further used the G␣ iq chimeric protein to examine the G protein coupling specificity of V gain and V ␤ . It has been shown that the substitution of the last four to five C-terminal amino acids of G␣ i with the corresponding residues of G␣ q makes the G␣ iq chimera couple to G␣ i -coupled receptors but signal through the G␣ q -mediated phospholipase C pathway (26, 31) . We made three G␣ iq chimeras and examined their effects on the G␣ q signaling pathway in V gain -and V ␤ -transfected cells using the pcDNA3.1 plasmid as a negative control and the dopamine D2 receptor as a positive control (Fig. 3G) . In pcDNA3.1-transfected cells, the overexpression of the three G␣ iq chimeras did not increase the activation of the G␣ q downstream NFAT reporter gene. However, after transfection with dopamine D2 receptor, V gain , or V ␤ , these chimeras rerouted signaling to the PLC ␤ -NFAT signaling pathway (Fig. 3H) . Notably, G␣ i1q , G␣ i2q , and G␣ i3q all increased the signaling of the PLC pathway in the presence of V gain and V ␤ , suggesting that V gain and V ␤ recognize all three G␣ i subtypes.
Structural Requirements for the G␣ i Protein Coupling of VLGR1-To further confirm that the constitutive activity of V gain and V ␤ are specific to G␣ i , we next looked for potential mutations that would specifically decouple the interaction between VLGR1 and G␣ i . In the recently solved ␤ 2 -adrenergic receptor⅐G␣ s complex crystal structure, intracellular loop 2 of the ␤ 2 -adrenergic receptor forms extensive interactions with the N terminus of G␣ s . In particular, (32) . This hydrophobic interaction may be a driving force for ␤ 2 -adrenergic receptor and G␣ s coupling. Assuming that the residues around intracellular loop 2 of VLGR1 are also important for G protein coupling, we examined the effects of mutating several conserved residues of VLGR1 (Fig. 4, A, B, and C) . All of the mutants had normal expression levels and did not affect the cell surface localization of the receptor. The Phe 5988 and Tyr 5990 mutations did not significantly affect the inhibitory activity of V gain , but the R6002A mutation eliminated the inhibition of V gain toward the forskolin-induced cAMP increase (Fig. 4 , B, C, and D). The R6002A mutant may directly impair G␣ i protein coupling ability as demonstrated by the G␣ iq chimera switching assay (Fig. 4E) . Although overexpression of G␣ i1q , G␣ i2q , or FIGURE 6. Regulation of VLGR1-G␣ i signaling by PDZD7. A, effects of Usher proteins on V gain -G␣ i or V gain -Y6236fsX1-G␣ i coupling. Equal amounts of Usher proteins, including Harmonin, Whirlin, and PDZD7, were co-expressed with V gain or V gain -Y6236fsX1. The forskolin-induced cAMP increase were monitored by GloSensor cAMP assay. Harmonin or Whirlin has no effect on AC inhibitory activity of V gain or V gain -Y6236fsX1. Although PDZD7 decouples V gain -G␣ i interaction, it has no effect on V gain -Y6236fsX1-G␣ i coupling. G␣ i3q promoted PLC signaling in the presence of the wild type V gain , they produced no effects in the presence of the R6002A V gain mutant. These results verified that the AC inhibitory activity was directly linked to the intact seven-transmembrane structure of VLGR1.
A Disease-associated Mutant Has a Gain of Function in G␣ i
Coupling-Among the disease-associated VLGR1 mutations, the VLGR1 human Y6244fsX1 caught our attention because it is located in the intracellular part of the receptor (3). We therefore made a mouse VLGR1 Y6236fsx1 mutant that corresponds with the human Y6244fsx1 cDNA. Notably, the pathogenic Y6236fsx1 mutation has a frameshift that eliminates the last 62 residues of the C terminus, producing a 39-kDa band after gel electrophoresis (Fig. 5A) . The Y6236fsx1 mutation did not change the plasma membrane receptor localization detected by immunofluorescence (Fig. 5D) . However, the introduction of the Y6236fsx1 mutation into V ␤ or V gain increased their inhibitory effects on AC activity as demonstrated by the GloSensor assay and phospho-CREB levels (Figs. 5, B and C, and 6, A-D). These results suggest that the pathogenic mutation Y6236fsx1 increases its G␣ i coupling ability.
PDZD7 Negatively Regulated G␣ i Coupling Activity in V gain and V ␤ -Because of its short C-terminal tail, the pathogenic VLGR1 Y6236fsx1 mutation may affect its binding to downstream effectors and contribute to its increased G␣ i coupling activity. We thus overexpressed three known VLGR1 C terminus-interacting partners, Harmonin, Whirlin, and PDZD7, all of which are involved in Usher syndrome, to investigate their effects on VLGR1-mediated AC inhibition (33, 34) . Interestingly, although overexpression of Harmonin or Whirlin had no effect on VLGR1-mediated AC inhibition, overexpression of the other Usher syndrome-related protein, PDZD7, inhibited both V gain -and V ␤ -mediated AC inhibition (Fig. 6, A-D) . However, the overexpression of PDZD7 did not block Y6236fx1-mediated AC inhibition (Fig. 6, A-D) . The specific inhibition of V ␤ but not V ␤ -Y6236fx1 activity by PDZD7 was also demonstrated in the neuronal glioblastoma (astrocytoma) cell line U251 (Fig. 6, E and F) .
Removing the C-terminal PDZ binding motif "DTHL" has been shown to significantly reduce the interaction between PDZD7 and the VLGR1 C-tail (1, 12) . The effects of a loss of PDZD7 on Y6236fx1 mutants may be due to the loss of the interaction between these two proteins. Consistent with this hypothesis, the V ␤ -Y6236fx1 mutation significantly reduced its interaction with PDZD7 compared with V ␤ (Fig. 6G ). In contrast, both the V gain -and V gain -R6002A mutants robustly coimmunoprecipitated with PDZD7 in equal amounts (Fig. 6H) . These results suggested that the Y6236fsx1 mutation improved VLGR1 inhibitory activity on AC likely due to the loss of interaction with its C-terminal binding partners, such as PDZD7. However, the loss of function in the R6002A mutant did not alter its interaction with PDZD7. Whether the gain of function in G␣ i signaling by the VLGR1 Y6236sfx1 mutant contributes to the development of Usher syndrome awaits further investigation.
Conclusion-In summary, we have demonstrated that the Usher protein VLGR1 can be separated into two subunits by autocleavage at its GPS. Without extracellular stimulation, the ␤-subunit of VLGR1 inhibits AC activity through G␣ i coupling. Its G␣ i coupling specificity was verified using site-directed mutagenesis, PTX interference, and receptor-G protein fusion proteins as well as co-expression with the G␣ iq chimeric protein. Moreover, the intracellular pathogenic mutation VLGR1 Y6236fsx1 had an increased constitutive activation of G␣ i signaling. The overexpression of the Usher protein PDZD7 blocked VLGR1 ␤-subunit-mediated AC inhibition, but PDZD7 had no effect on Y6236fsx1 mutant-mediated AC inhibition. Recent studies have identified the digenic inheritance of PDZD7 and VLGR1 as well as the physical interaction between PDZD7 and the VLGR1 C terminus. However, the molecular mechanism underlying this genetic linkage is unclear (12, 35) . The association of the Usher protein PDZD7 as well as the Usher mutant VLGR1 Y6236fsx1 with G␣ i activity suggests a potential role for VLGR1-mediated G␣ i signaling in Usher disease development.
Recently, a parallel work showed that a recombinant VLGR1 truncation protein senses extracellular calcium, activates G␣ s and G␣ q signaling, and regulates the stability of myelin-associated glycoprotein, which is important for the prevention of audiogenic epilepsy (14) . Although the reported G protein subtype signaling downstream of VLGR1 is different from that in our study, the known beneficial effects of AC activation in the prevention of audiogenic epilepsy are logically consistent with our finding that the disease-associated VLGR1 mutant inhibited AC activity (14) . Moreover, the switching of G protein coupling specificity in different physiological/pathological conditions has been demonstrated in other GPCRs, such as the ␤ 2 -adrenergic receptor in which the receptor phosphorylation by PKA switched its coupling from G␣ s to G␣ i (36, 37) . Our result showed that V ␤ has stronger G␣ i coupling activity than V gain , suggesting that the N-terminal fragment has an inhibitory role in VLGR1 activity. Thus, it is likely that the cleaved V ␤ subunit signals independently and switched the VLGR1 G protein coupling specificity. Taken together, our data show the constitutive G␣ i coupling activity of the VLGR1 ␤-subunit and the regulation of this activity by the N terminus of VLGR1, a disease-associated mutant, and the Usher protein PDZD7. This study may shed light on the molecular mechanisms underlying Usher syndrome.
